Literature DB >> 17117686

Progress toward the discovery and development of efficacious BACE inhibitors.

Timothy B Durham1, Timothy A Shepherd.   

Abstract

BACE (beta-site amyloid precursor protein [APP] cleavage enzyme) is a transmembrane aspartyl protease responsible for the first cleavage event in the processing of APP to Abeta peptide. Amyloid plaques composed of Abeta peptides are hypothesized to be the root cause of neuronal cell death in Alzheimer's disease patients. Thus, BACE has become a target of significant interest for pharmaceutical and academic research. The recent literature relating to the discovery and development of efficacious BACE inhibitors is reviewed with particular emphasis on the patent literature.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17117686

Source DB:  PubMed          Journal:  Curr Opin Drug Discov Devel        ISSN: 1367-6733


  16 in total

Review 1.  Alzheimer's disease: strategies for disease modification.

Authors:  Martin Citron
Journal:  Nat Rev Drug Discov       Date:  2010-05       Impact factor: 84.694

Review 2.  The influence of lead discovery strategies on the properties of drug candidates.

Authors:  György M Keserü; Gergely M Makara
Journal:  Nat Rev Drug Discov       Date:  2009-03       Impact factor: 84.694

3.  Design and synthesis of novel methoxypyridine-derived gamma-secretase modulators.

Authors:  Kevin D Rynearson; Ronald N Buckle; R Jason Herr; Nicholas J Mayhew; Xinchao Chen; William D Paquette; Samuel A Sakwa; Jinhai Yang; Keith D Barnes; Phuong Nguyen; William C Mobley; Graham Johnson; Juinn H Lin; Rudolph E Tanzi; Steven L Wagner
Journal:  Bioorg Med Chem       Date:  2020-09-01       Impact factor: 3.641

4.  Molecular shape and medicinal chemistry: a perspective.

Authors:  Anthony Nicholls; Georgia B McGaughey; Robert P Sheridan; Andrew C Good; Gregory Warren; Magali Mathieu; Steven W Muchmore; Scott P Brown; J Andrew Grant; James A Haigh; Neysa Nevins; Ajay N Jain; Brian Kelley
Journal:  J Med Chem       Date:  2010-05-27       Impact factor: 7.446

Review 5.  beta-Secretase as a therapeutic target for Alzheimer's disease.

Authors:  Arun K Ghosh; Sandra Gemma; Jordan Tang
Journal:  Neurotherapeutics       Date:  2008-07       Impact factor: 7.620

6.  The expression of microRNA miR-107 decreases early in Alzheimer's disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1.

Authors:  Wang-Xia Wang; Bernard W Rajeev; Arnold J Stromberg; Na Ren; Guiliang Tang; Qingwei Huang; Isidore Rigoutsos; Peter T Nelson
Journal:  J Neurosci       Date:  2008-01-30       Impact factor: 6.167

Review 7.  Neuronal protein trafficking associated with Alzheimer disease: from APP and BACE1 to glutamate receptors.

Authors:  Bor Luen Tang
Journal:  Cell Adh Migr       Date:  2009-01-21       Impact factor: 3.405

Review 8.  The normal and pathologic roles of the Alzheimer's β-secretase, BACE1.

Authors:  Patty C Kandalepas; Robert Vassar
Journal:  Curr Alzheimer Res       Date:  2014       Impact factor: 3.498

Review 9.  Treatment strategies targeting amyloid β-protein.

Authors:  Dale Schenk; Guriqbal S Basi; Menelas N Pangalos
Journal:  Cold Spring Harb Perspect Med       Date:  2012-09-01       Impact factor: 6.915

10.  Amyloid precursor family proteins are expressed by thymic and lymph node stromal cells but are not required for lymphocyte development.

Authors:  Karen Laky; Willem Annaert; B J Fowlkes
Journal:  Int Immunol       Date:  2009-08-26       Impact factor: 4.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.